Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.72 - $45.93
Previous CloseN/A
Volume981.79K
Average Volume (3M)4.73M
Market Cap
$74.11B
Enterprise Value$85.76B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)22.7
Beta0.37
Next Earnings
Apr 30, 2025EPS Estimate
1.03Last Dividend Ex-Date
Feb 21, 2025Dividend Yield4.18%
Share Statistics
EPS (TTM)1.60
Shares Outstanding2,072,972,700
10 Day Avg. Volume5,254,691
30 Day Avg. Volume4,728,290
Standard Deviation0.07
R-Squared0.25
Alpha-0.00666
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.90
Price to Cash Flow (P/CF)14.40
P/FCF Ratio22.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.98Price Target Upside-1.53% Downside
Rating ConsensusHold
Number of Analyst Covering4
---
Ownership Overview
―
Insiders
4.96% Mutual Funds
9.86% Other Institutional Investors
84.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $31.71 and its highest was $45.92 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $74.11B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Apr 30, 2025 which is in 68 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Feb 05, 2025. The company reported $0.581 earnings per share for the quarter, beating the consensus estimate of $0.489 by $0.092.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $0.393 which represents an annual dividend yield of 4.18%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 1.03.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,072,972,700 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $0.581 in its last earnings report, beating expectations of $0.489. Following the earnings report the stock price went up 8.209%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
---
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$35.98 (-1.53% Downside)
$35.98 (-1.53% Downside)
Blogger Sentiment
Bullish
GSK Sentiment 91%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.50%
12-Months-Change
Fundamentals
Return on Equity
19.11%
Trailing 12-Months
Asset Growth
-0.99%
Trailing 12-Months
Company Description
GlaxoSmithKline
Founded in 1715 and headquartered in Brentford, U.K., GlaxoSmithKline Plc is a global healthcare company which develops and manufactures pharmaceutical medicines in therapeutic areas, vaccines and consumer healthcare products in wellness, oral health, nutrition, and skin health categories.
---
GSK Company Deck
---
GSK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and growth in specialty medicines, particularly in oncology and HIV. However, there are notable challenges in the vaccines segment and financial impacts from litigation and regulatory changes. Overall, the positive aspects and future growth prospects outweigh the current challenges.Read More>---
GSK Stock 12 Month Forecast
Average Price Target
$35.98
▼(-1.53% Downside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-3.81%
reiterated a sell rating 3 months ago
Copying Graham Parry's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -3.81% per trade.
---